Business Description
Ectin Research AB
ISIN : SE0015987714
Compare
Compare
Traded in other countries / regions
ECTIN B.Sweden IPO Date
2021-08-18Description
Ectin Research AB is a pharmaceutical company developing a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370 engages in the treatment of metastatic bladder cancer, and has also shown potential in other cancers such as breast, colorectal and prostate cancer cells.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8 | |||||
| Equity-to-Asset | 0.65 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -215.9 | |||||
| 3-Year EPS without NRI Growth Rate | -145.6 | |||||
| 3-Year Book Growth Rate | -26.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.32 | |||||
| 9-Day RSI | 39.9 | |||||
| 14-Day RSI | 40.39 | |||||
| 6-1 Month Momentum % | -28.78 | |||||
| 12-1 Month Momentum % | -34.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.28 | |||||
| Quick Ratio | 4.28 | |||||
| Cash Ratio | 3.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -111.53 | |||||
| ROA % | -97.94 | |||||
| ROIC % | -104.45 | |||||
| ROC (Joel Greenblatt) % | -145762.71 | |||||
| ROCE % | -106.31 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.18 | |||||
| Price-to-Tangible-Book | 1.19 | |||||
| EV-to-EBIT | 0.01 | |||||
| EV-to-EBITDA | 0.01 | |||||
| EV-to-FCF | 0.02 | |||||
| Price-to-Net-Current-Asset-Value | 1.19 | |||||
| Price-to-Net-Cash | 1.4 | |||||
| Earnings Yield (Greenblatt) % | No Debt | |||||
| FCF Yield % | -152.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ectin Research AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -1.37 | ||
| Beta | 0 | ||
| Volatility % | 145.36 | ||
| 14-Day RSI | 40.39 | ||
| 14-Day ATR (kr) | 0.07702 | ||
| 20-Day SMA (kr) | 0.4613 | ||
| 12-1 Month Momentum % | -34.25 | ||
| 52-Week Range (kr) | 0.29 - 1 | ||
| Shares Outstanding (Mil) | 12.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ectin Research AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ectin Research AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ectin Research AB Frequently Asked Questions
What is Ectin Research AB(XSAT:ECTIN B)'s stock price today?
The current price of XSAT:ECTIN B is kr0.39. The 52 week high of XSAT:ECTIN B is kr1.00 and 52 week low is kr0.29.
When is next earnings date of Ectin Research AB(XSAT:ECTIN B)?
The next earnings date of Ectin Research AB(XSAT:ECTIN B) is 2024-05-21.
Does Ectin Research AB(XSAT:ECTIN B) pay dividends? If so, how much?
Ectin Research AB(XSAT:ECTIN B) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers